Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20622Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pavlidis, N. | en |
| dc.contributor.author | Nikolaou, N. | en |
| dc.contributor.author | Tolis, C. | en |
| dc.contributor.author | Orfanos, S. | en |
| dc.contributor.author | Tolis, G. | en |
| dc.date.accessioned | 2015-11-24T19:08:56Z | - |
| dc.date.available | 2015-11-24T19:08:56Z | - |
| dc.identifier.issn | 0098-1532 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20622 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use | en |
| dc.subject | Bone Marrow/drug effects | en |
| dc.subject | Bone Marrow Diseases/*chemically induced/drug therapy | en |
| dc.subject | Hodgkin Disease/complications/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Hypogonadism/complications/*drug therapy | en |
| dc.subject | Male | en |
| dc.subject | Mechlorethamine/administration & dosage/adverse effects | en |
| dc.subject | Pituitary Hormone-Releasing Hormones/deficiency | en |
| dc.subject | Prednisone/administration & dosage/adverse effects | en |
| dc.subject | Procarbazine/administration & dosage/adverse effects | en |
| dc.subject | Testosterone/*therapeutic use | en |
| dc.subject | Vincristine/administration & dosage/adverse effects | en |
| dc.title | Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/2664441 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1002/mpo.2950170310/asset/2950170310_ftp.pdf?v=1&t=h0niod8i&s=37f7afb73cb548fe7873ba069ed4a7d3a86a6f5a | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1989 | - |
| heal.abstract | A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life-threatening myelosuppression; androgen substitution seemed to reverse bone marrow function and to maintain normal peripheral blood counts. Whether or not androgens are a necessary substitution in hypogonadal patients suffering from cancer and undergoing chemotherapy is discussed. | en |
| heal.journalName | Med Pediatr Oncol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Pavlidis-1989-Is androgen substitu.pdf | 368 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
